Molecular Biology of Breast Cancer

Essential Concepts in Molecular Pathology

Volumn 9780123744180, Issue , 2010, Pages 341-349

  Snoj, Natasa ^a   Dinh, Phuong ^a   Bedard, Philippe ^a   Sotiriou, Christos ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884578034     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374418-0.00026-8     Document Type: Chapter

References (19)

1. Berry D.A., Cirrincione C., Henderson C., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. J Am Med Assoc. 2006, 295(14):1658-1667.
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 365(9472):1687-1717. Early Breast Cancer Trialists' Collaborative Group.
3. Goldhirsch A., Ingle J.N., Gelber R.D., et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009.
4. Harvey J.M., Clark G.M., Osborne C.K., et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999, 17(5):1474-1481.
5. Horowitz K.B., McGuire W.L. Predicting response to endocrine therapy in human breast cancer: A hypothesis. Science 1975, 189(4204):726-727.
6. Kuerer H.M., Albarracin C.T., Yang W.T., et al. Ductal carcinoma in situ: State of the science and roadmap to advance the field. J Clin Oncol. 2009, 27(2):279-288.
7. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004, 351(27):2817-2826.
8. Paik S., Shak S., Tang G., et al. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [abstract]. J Clin Oncol. 2005, 23(suppl 16):510. (Meeting Abstracts).
9. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
10. Pestalozzi B.C., Zahrieh D., Mallon E., et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: Combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008, 26(18):3006-3014.
11. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005, 353(16):1659-1672.
12. Rakha E.A., El-Sayed M.E., Lee A.H., et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008, 26(19):3153-3158.
13. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005, 353(16):1673-1684.
14. Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996, 14(10):2738-2746.
15. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006, 98(4):262-272.
16. van't Veer L.J. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
17. van de Vijver M.J. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347:1999-2009.
18. Wirapati P., Sotiriou C., Kunkel S., et al. Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10(4):R65.
19. Wolff A.C., Hammond M.H., Scwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007, 25(1):118-145.